Tocqueville Asset Management L.P. Tg Therapeutics, Inc. Transaction History

Tocqueville Asset Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $211,280 - $493,589	-13,900 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $43,560 - $80,900	-2,000 Reduced 12.58%	13,900 $463,000
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $69,875 - $105,264	2,150 Added 15.64%	15,900 $617,000
Q1 2021 May 17, 2021	BUY	$41.61 - $54.3 $16,644 - $21,720	400 Added 3.0%	13,750 $663,000
Q4 2020 Feb 16, 2021	SELL	$25.27 - $54.9 $29,060 - $63,135	-1,150 Reduced 7.93%	13,350 $694,000
Q3 2020 Nov 16, 2020	BUY	$18.49 - $27.24 $46,224 - $68,100	2,500 Added 20.83%	14,500 $388,000
Q2 2020 Aug 12, 2020	BUY	$8.9 - $21.84 $106,800 - $262,080	12,000 New	12,000 $234,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.